tradingkey.logo

tradingkey.logo
怜玢


ENDRA Life Sciences Inc

NDRA
りォッチリストに远加
4.610USD
+0.280+6.47%
終倀 07-31 16:00ET15分遅れの株䟡
5.42M時䟡総額
損倱額盎近12ヶ月PER

詳现情報 ENDRA Life Sciences Inc 䌁業名

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

ENDRA Life Sciences Incの䌁業情報


䌁業コヌドNDRA
䌚瀟名ENDRA Life Sciences Inc
䞊堎日Jun 28, 2017
最高経営責任者「CEO」Tokman (Alexander Y)
埓業員数21
蚌刞皮類Ordinary Share
決算期末Jun 28
本瀟所圚地3600 Green Ct Ste 350
郜垂ANN ARBOR
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号48105
電話番号17343350468
りェブサむトhttps://www.endrainc.com/
䌁業コヌドNDRA
䞊堎日Jun 28, 2017
最高経営責任者「CEO」Tokman (Alexander Y)

ENDRA Life Sciences Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
76.27K
+7.06%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
76.27K
+7.06%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--

よくある質問

ENDRA Life Sciences Incの䞊䜍5名の株䞻は誰ですか


ENDRA Life Sciences Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Anthony DiGiandomenico

ENDRA Life Sciences IncNDRAの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、ENDRA Life Sciences Incの株匏を保有しおいる機関は30瀟あり、保有株匏の総垂堎䟡倀は玄218.33Kで、党䜓の17.60%を占めおいたす。2025Q4ず比范しお、機関の持ち株は137855.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。